Follow up | ||||||||
---|---|---|---|---|---|---|---|---|
Variable | Inclusion (baseline) | 6 weeks | 12 weeks | 6 months | 12 months | 18 months | 24 months | 12 (± 1) months after ATD treatment withdrawal† |
Visit | x | x | x | |||||
ATD treatment | x | x | x | |||||
Thyroid function | x1 | x1 | x1 | |||||
TSH-Receptor Antibodies | x1 | xs | xs | |||||
Serum selenium | x | (xs) | (xs) | |||||
Creatinine/iodine ratio in spot urine | x | |||||||
Storage samples (blood and urine) | x | x | x | |||||
ThyPRO | xr | xr | xr | xr | xr | xr | xr | xr |
Tablet count | xr | xr | xr | xr | xr | xr | xr | |
Consumption of additional selenium | xr | xr | xr | xr | ||||
Adverse events* | xr | xr | xr | xr | xr | xr | xr | |
Serious adverse events | x | |||||||
Referral to ablative therapy | x | x |